This site might not work as expected.
You're using an old browser that isn't supported by this site. Please upgrade or download one of these free and excellent browsers:

What's the Impact of New Marijuana Laws? The Data So Far…

How has new legislation affected marijuana use in the United States? The best available data suggest that marijuana use is increasing in adults but not teens, with a decrease in marijuana-related arrests but an increase in treatment admissions, according to an update in the January/February Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM). The journal is published by Wolters Kluwer.

The review by Jane C. Maxwell, PhD, of The University of Texas at Austin and Bruce Mendelson, MPA, of the Denver Office of Drug Strategy gives insights into the initial impact of legalizing or decriminalizing marijuana in some states. "Data are needed to understand the relationship between the patterns and amounts of use in terms of consequences as well as data on the health conditions of those receiving medical marijuana and the impact of higher potency," the authors write.

Rising Rate of Marijuana Use, with Some Evidence of Harmful Effects

Maxwell and Mendelson provide an update on recent state laws regarding marijuana and analyze available data on how those laws are affecting rates of marijuana use, attitudes toward marijuana, and other key issues. A few states have legalized possession/use of small amounts of marijuana, while several others have "decriminalized" marijuana. Most states now permit some types of "medical marijuana" use.

Data from the National Survey on Drug Use and Health suggest that, over the past decade, marijuana use has increased significantly among adults aged 18 to 25 and those aged 26 years and older. These trends appear to have begun before 2012, when Colorado and Washington became the first states to legalize marijuana.

Meanwhile, marijuana use by youth aged 12 to 17 has not increased significantly. However, young people's perceptions of the risks of using marijuana have decreased, suggesting that they may be more likely to start using marijuana in the future.

Studies have consistently shown that the potency of marijuana is increasing. Data from California suggest that marijuana is more widely available, and that more drivers are testing positive for it.

Initial reports from Colorado and Washington State provide evidence on the effects of legalization. In Denver, marijuana-related hospital admissions, emergency department visits, and calls to poison control centers have all increased. At the same time, arrests for marijuana use/possession and admissions to substance use disorder treatment programs have decreased.

Data from the Seattle area also show reduced rates of treatment admissions and police involvement, along with an increased prevalence of frequent marijuana use.

The lack of data on the characteristics of the users of medical marijuana, their medical conditions, and use patterns, as well as adverse events they may suffer by using different variations of the drug is an important knowledge gap. Data are needed to understand the relationship between the patterns and amounts of use in terms of consequences, as well as on the health conditions of those receiving medical marijuana and the impact of higher potency.

The authors hope their review will provide a useful starting point for evaluating the impact of changes in marijuana legislation. They write, "As more states enact laws allowing the medicinal use of marijuana and relax penalties for the personal use of marijuana, attention should be paid to the experiences of the states to date and changes in their laws to handle unanticipated problems."

Read What Do We Know Now About the Impact of the Laws Related to Marijuana?.

Article: “What Do We Know Now About the Impact of the Laws Related to Marijuana?” (doi: 10.1097/ADM.0000000000000188)

About Journal of Addiction Medicine

The mission of Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical specialty. Published quarterly, the Journal is designed for all physicians and other mental health professionals who need to keep up-to-date with the treatment of addiction disorders. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics.

About The American Society of Addiction Medicine

The American Society of Addiction Medicine is a national medical specialty society of over 3,600 physicians and associated health professionals. Its mission is to increase access to and improve the quality of addiction treatment, to educate physicians, and other health care providers and the public, to support research and prevention, to promote the appropriate role of the physician in the care of patients with addictive disorders, and to establish addiction medicine as a specialty recognized by professional organizations, governments, physicians, purchasers and consumers of health care services and the general public. ASAM was founded in 1954, and has had a seat in the American Medical Association House of Delegates since 1988. Follow ASAM’s official Twitter handle: @ASAMorg

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.